Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)
August 5, 2022 07:19 AM EDTUpdated 01:41 PM
Pharma
Marketing

Am­gen diss­es drug pric­ing bill, while amp­ing $4B rare drug com­pa­ny deal and up­com­ing Hu­mi­ra biosim launch

Beth Snyder Bulik

Senior Editor

Add Am­gen CEO Bob Brad­way to the cho­rus of phar­ma CEOs lament­ing the pend­ing drug pric­ing leg­is­la­tion in the US Sen­ate.

“For some time, we …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times